Virus is associated with sickness, but oncolytic virus therapies, which harness viruses to attack and kill cancer cells, may soon change the standard of treatment for cancer, including those long deemed uncurable like malignant glioma.
A study presented at the American Society for Radiation Oncology on Oct. 1 offers promise for the treatment of high-grade gliomas using Elekta AB’s Unity MR-Linac system.
Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of glioblastoma.
Adaptin Bio has obtained IND clearance from the FDA for APTN-101 in glioblastoma, enabling initiation of a first-in-human phase I trial in patients diagnosed with WHO grade IV malignant glioma.
Tumor protein p73 (TP73) has been commonly tagged as a putative tumor suppressor, but it may positively regulate the growth and stemness of cancer stem cells.
Diakonos Oncology Corp. has developed a process to manufacture dendritic cell vaccines that the company believes are substantially more potent than its predecessors.
Kazia Therapeutics Ltd.'s stock shot up 248% on July 10 after the Sydney-based company reported that paxalisib showed a 3.8-month improvement in overall survival, a 33% improvement, for newly diagnosed unmethylated patients with glioblastoma (GBM) compared to the concurrent standard-of-care arm in the pivotal GBM-Agile phase II/III study.
